膜细胞淋巴瘤 - - 关于分子生物学,预后和治疗方法的最新信息
Elisabeth Silkenstedt1, Martin Dreyling1
1Department of Medicine III, LMU University Hospital, Munich, Germany.
Hematological oncology
|June 9, 2023
概括
膜细胞淋巴瘤 (MCL) 是一种多样化的癌症. 新的免疫疗法改善了结果,但基于风险的个性化治疗是改善患者管理的关键.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 膜细胞淋巴瘤 (MCL) 呈现异质的临床行为,从惰到积极的形式.
- 由于有针对性和免疫治疗的进步,目前的治疗选择有所改善,特别是在复发性或耐火性MCL中.
研究的目的:
- 审查目前关于MCL生物学和护理标准的知识.
- 突出新型免疫治疗方法在MCL治疗中的整合.
- 强调需要适应风险,为患者量身定制的治疗策略.
主要方法:
- 对当前的知识和MCL护理标准的文献综述.
- 分析针对性和免疫治疗策略的最新进展.
- 关于实施个性化治疗风险分层的讨论.
主要成果:
- MCL提供了广泛的临床过程和预后.
- 新的向和免疫疗法提高了治疗效率,特别是在难以治疗的病例中.
- 早期风险识别对于优化治疗策略至关重要.
结论:
- 优化MCL治疗需要早期风险分析和量身定制的治疗选择.
- 整合针对免疫系统的新型免疫疗法对于改善患者结果至关重要.
- 对临床患者管理来说,有望纳入风险适应策略是必不可少的.
相关概念视频
Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


